Skip to main content

Table 1 Comparison of Provider-Perceived Efficacy of Buprenorphine vs. Extended-Release Naltrexone. Detailed Table Summary: Respondents believed that buprenorphine decreases opioid cravings more than extended-release naltrexone (paired t [37]=4.474, p < 0.001). Respondents believed that buprenorphine, to a greater degree than extended-release naltrexone, decreases the risk of fatal opioid-overdose (paired t [38]=3.413, p = 0.001), decreases return to opioid misuse (paired t [39]=2.078, p = 0.043), and works well in patients with co-occurring mental health disorders (paired t [39]=2.461, p = 0.017).

From: A mixed-method comparison of physician-reported beliefs about and barriers to treatment with medications for opioid use disorder

Perceptions Buprenorphine Naltrexone t df Mean of the Difference Cohen’s d 95% Confidence Interval p
n Mean (SD) n Mean (SD) Lower Upper
MOUD decreases risk of death from opioid overdose 52 4.327 (1.024) 52 3.769 (0.921) 3.413 51 0.558 0.755 0.230 0.885 0.001*
MOUD decreases cravings for opioids 53 4.491 (0.869) 53 3.566 (1.118) 4.474 52 0.925 0.924 0.510 1.339 < 0.001*
MOUD decreases rates of relapse 50 4.200 (1.030) 50 3.840 (0.792) 2.078 49 0.360 0.392 0.012 0.708 0.043*
MOUD works well in patients with co-occurring mental health disorders 50 4.220 (0.996) 50 3.780 (0.954) 2.461 49 0.440 0.451 0.081 0.799 0.017*
MOUD should be supplemented by mental health counseling 56 4.571 (0.806) 56 4.393 (0.846) 1.563 55 0.179 0.215 −0.050 0.408 0.124
MOUD should be supplemented by participation in peer support groups 57 4.298 (0.999) 57 4.193 (1.043) 0.973 56 0.105 0.103 −0.111 0.322 0.335
MOUD efficacy is improved by adding mental health counseling 56 4.518 (0.853) 56 4.429 (0.828) 0.962 55 0.089 0.106 −0.0979 0.2756 0.001*
  1. Notes: MOUD medication for opioid use disorder. Questions asked about the MOUDs buprenorphine and extended-release naltrexone were compared in these results using paired samples t-tests (alpha = 0.05, two-tailed level). * indicates significance at the α = .05 level
Back to article page

Substance Abuse Treatment, Prevention, and Policy

ISSN: 1747-597X